Retinoids: new use by innovative drug-delivery systems
Abstract
BACKGROUND: Retinoids represent an old class of bioactives used in the treatment of different skin pathologies (such as acne and psoriasis) and in the treatment of many tumors. Unfortunately, they present several side effects, i.e., burning of skin and general malaise after systemic administration and they are very unstable after exposition to light. METHODS: One of the most promising new approaches for reducing the side effects of retinoids while improving their pharmacological effect is the use of drug-delivery devices. This review explains the current status of retinoid drug transport, which has been developing over the last few years, explaining the modification of their biopharmaceutical properties in detail after encapsulation/inclusion in vesicular and polymeric systems. RESULTS/CONCLUSION: Different colloidal and micellar systems containing retinoid drugs have been realized furnishing important potential advancements in traditional therapy.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
NO2-cLA is found basally in the plasma and urine of healthy humans and its concentrations increase in organelles and tissues undergoing metabolic and inflammatory stress.
“NO2-cLA is found basally in the plasma and urine of healthy humans and its concentrations increase in organelles and tissues undergoing metabolic and inflammatory stress [3, 16] (Fig. 5).”
From Nitrite and nitrate-dependent generation of anti-inflammatory fatty acid nitroalkenes (2015) · cites this paper as [16]
The citation lists haven’t been fetched yet
References 70 · Cited by 49
- Authors
- Trapasso, E., Cosco, D., Celia, C., Fresta, M., & Paolino, D.
- Affiliations
- University of Messina (IT)
- Magna Graecia University (IT)
- Venue
- Expert Opinion on Drug Delivery
- Publisher
- Informa Healthcare
- Published
- 2009-05
- Volume
- 6
- Issue
- 5
- Pages
- 465-483
- ISSN
- 1742-5247 (ISSN-L)
- 1744-7593
- OpenAlex
- W2123928598
- Cited by
- 49
- References
- 70
- Citations by year
- 2026: 2 · 2025: 1 · 2024: 2 · 2023: 2 · 2022: 2 · 2021: 3 · 2020: 2 · 2019: 2 · 2018: 2 · 2017: 3 · 2016: 4 · 2015: 3 · 2014: 2 · 2013: 7 · 2012: 4
- FWCI
- 2.72
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Expert Opinion on Drug Delivery (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmaceutical Science › Advancements in Transdermal Drug Delivery
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmaceutical Science › Advanced Drug Delivery Systems
- Physical Sciences › Materials Science › Biomaterials › Nanoparticle-Based Drug Delivery
- Keywords
- retinoids, drug delivery systems, vesicular systems, polymer systems, colloids, micellar systems, encapsulation, inclusion complexes, dermatopathology, acne, psoriasis, cancer therapy, photostability, adverse effects
- MeSH terms
- Animals, Drug Carriers, Humans, Liposomes, Models, Molecular, Polymers, Retinoids, Drug Delivery Systems, Nanoparticles
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
